AP NEWS

EMMAC Life Sciences PLC Announces Turnkey GMP Facility in Malta to be Group Import and Distribution Hub

February 5, 2019

LONDON--(BUSINESS WIRE)--Feb 5, 2019--EMMAC, (“EMMAC” or the “Company”) the European independent medical cannabis company, is pleased to announce that Malta Enterprise, the Maltese government’s exclusive agency focused on attracting inward investment and supporting enterprise in Malta, has granted EMMAC a Letter of Intent under terms of the Production of Cannabis for Medicinal Use Act, 2018, Chapter 578 of the Laws of Malta. The Letter of Intent is preliminary approval for the issuance of a full license (covering cultivation / production / importation / exportation) under the terms of the Production of Cannabis for Medicinal Use Act, 2018.

The Turnkey GMP facility in Malta will be EMMAC’s importation, exportation, testing and distribution hub for Europe and other international markets.

Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to have had such strong support from the Maltese Government and relevant public and regulatory authorities. As the demand for premium quality medical cannabis continues to grow, our facility in Malta will form a critical part of EMMAC’s unique European infrastructure as our group import and distribution hub.”

About EMMAC

EMMAC Life Sciences PLC is the European medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.

Contact:

For scientific enquiries please contact research@emmac.com

For general enquiries please contact info@emmac.com or visit www.emmac.com

CAUTIONARY STATEMENT

All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences PLC. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.

Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences PLC assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190204005369/en/

CONTACT: Media enquiries:

Buchanan

Henry Harrison-Topham / Jamie Hooper / Catriona Flint

emmac@buchanan.uk.com

Tel: +44 (0) 20 7466 5000

www.buchanan.uk.com

KEYWORD: UNITED KINGDOM MALTA EUROPE

INDUSTRY KEYWORD: HEALTH PUBLIC POLICY/GOVERNMENT ONCOLOGY PHARMACEUTICAL OTHER GOVERNMENT OTHER HEALTH OTHER SCIENCE SCIENCE MANAGED CARE

SOURCE: EMMAC Life Sciences PLC

Copyright Business Wire 2019.

PUB: 02/05/2019 02:00 AM/DISC: 02/05/2019 02:00 AM

http://www.businesswire.com/news/home/20190204005369/en

AP RADIO
Update hourly